Experienced consultant, physician, and digital health tech innovator Peter Alperin, M.D., joins Medixine as part of the company’s strategic focus on U.S. market growth. The appointment will facilitate the establishment of new partnerships in the United States and expand the deployment of Medixine’s physician and patient-centric remote patient monitoring solutions as a white-label-friendly offering in a market projected to exceed USD 25 billion by 2028.
ESPOO, Finland (February 27th, 2025) Finnish health tech company and remote patient monitoring (RPM) platform provider Medixine is continuing its strategic U.S. market expansion with the appointment of U.S.-based Senior Advisor Dr. Peter Alperin, M.D..
Alperin, an experienced digital medtech developer, will advise on strategic expansion and market positioning, strengthening Medixine’s already established foothold in the U.S., where the company has worked with multiple partners. Alperin’s appointment is Medixine’s second U.S.-based hire, following its Chicago-based VP of U.S. Operations, as the company advances its plans to establish a U.S.-based subsidiary.
Alperin brings decades of experience in physician-focused technology solutions, digital medtech product development, and a deep understanding of the unique U.S. market landscape. His background includes helping develop the mobile drug reference platform Epocrates, and a tenure as Vice President of Product at Doximity, the largest digital network for medical professionals in the U.S., used by around 80% of U.S. physicians.
The adoption of remote patient monitoring continues to grow steadily in the U.S. as hospitals and healthcare systems seek innovative ways to enhance patient care while optimizing resources and reducing costs. An additional advantage of Medixine’s RPM platform is its ease of integration and scalability as a white-label solution. This allows hospitals and healthcare organizations to quickly and cost-effectively deploy digital remote monitoring tools into their existing operations under their own trusted brand identity – a key factor in the competitive U.S. healthcare market.
“Remote patient monitoring is transforming healthcare delivery in the United States, particularly in addressing critical challenges like rural healthcare access and chronic condition management,” said Alperin. “Building a digital service solution from scratch can take months or even years of development, testing, and deployment. What drew me to Medixine, along with its physician- and patient-centric approach, is the platform’s ability to strengthen hospital-patient relationships as a tested, reliable white-label offering. This is especially important for healthcare providers in the US, where maintaining brand continuity is crucial for patient trust and engagement. I’m excited to help expand Medixine’s impact and bring its innovative technology to a wider audience.”
White-labeling an existing, proven technology platform not only allows healthcare providers to sidestep the significant financial and time costs of building and developing a proprietary solution from scratch, it also offers increased scalability and flexibility. Unlike static, custom-built platforms, white-labeled SaaS solutions benefit from continued expert support and adaptability to evolving customer or industry needs with minimal redevelopment from the user.
“We focus fully on our customers’ needs, allowing them to white label the solution, tailor it to their unique requirements, and support them so that they can focus on their core business under their own brand. We take care of the technology and allow them to grow their business without worrying about investing in software development,” says Lasse Rousi, CEO of Medixine.
As an accomplished physician and Assistant Professor at the University of Texas, Alperin’s deep understanding of the challenges faced by healthcare providers is another key asset. His expertise in physician-technology interface and digital health tech product development complement Medixine’s commitment to creating RPM services that improve patient care, comfort, and convenience while streamlining and optimizing clinical workflows.
“We see the U.S. as a key market for Medixine, and Peter’s appointment is another strategic step in accelerating our expansion,” Rousi continues. “His extensive experience in both clinical practice and healthcare technology, combined with his track record in scaling up successful healthcare platforms, will be invaluable in guiding our efforts. We’re particularly excited to see how his insights will help us further develop our offering to meet the unique needs of U.S. healthcare providers.”
Lasse Rousi
CEO
+358 401 845 793
lasse.rousi@medixine.com